47-year-old BethAnn Telford will run 7 marathons on 7 continents in 7 days. In 2005, she was diagnosed with brain cancer.
In honor of our annual AHC Day, AHCF is excited to announce that we will be able to fund two research projects to get us one step closer to a treatment for AHC!
Tesaro has opened up an expanded access program (EAP) for their PARP inhibtor, niraparib for ovarian cancer patients.
Saad Usmani, MD, FACP, of the Levine Cancer Institute talks about the convenience and safety of subcutaneous delivery of daratumumab in multiple myeloma patients.
Global Genes and Horizon Pharma are partnering up to provide scholarships to nephropathic cystinosis patients for future schooling and career opportunities.
Tomorrow, January 18th, is AHC day. AHC or alternating hemiplegia of childhood, is a devastating neurological disease caused by a mutation in the gene ATP1A3.
Pulmatrix's drug PUR1900 designed to treat fungal infections in the lungs of cystic fibrosis patients received Qualified Infectious Disease Product designation
CTD Holding's treatment for Niemann-Pick Disease Type C (NPC) got Fast Tracked by the FDA and will go into a Phase 1 trial.